Antimycobacterial Activity, Synergism, and Mechanism of Action Evaluation of Novel Polycyclic Amines against Mycobacterium tuberculosis
Mycobacterium tuberculosis has developed extensive resistance to numerous antimycobacterial agents used in the treatment of tuberculosis. Insufficient intracellular accumulation of active moieties allows for selective survival of mycobacteria with drug resistance mutations and accordingly promotes t...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Advances in Pharmacological and Pharmaceutical Sciences |
| Online Access: | http://dx.doi.org/10.1155/2021/5583342 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561508871045120 |
|---|---|
| author | Erika Kapp Jacques Joubert Samantha L. Sampson Digby F. Warner Ronnett Seldon Audrey Jordaan Margaretha de Vos Rajan Sharma Sarel F. Malan |
| author_facet | Erika Kapp Jacques Joubert Samantha L. Sampson Digby F. Warner Ronnett Seldon Audrey Jordaan Margaretha de Vos Rajan Sharma Sarel F. Malan |
| author_sort | Erika Kapp |
| collection | DOAJ |
| description | Mycobacterium tuberculosis has developed extensive resistance to numerous antimycobacterial agents used in the treatment of tuberculosis. Insufficient intracellular accumulation of active moieties allows for selective survival of mycobacteria with drug resistance mutations and accordingly promotes the development of microbial drug resistance. Discovery of compounds with new mechanisms of action and physicochemical properties that promote intracellular accumulation, or compounds that act synergistically with other antimycobacterial drugs, has the potential to reduce and prevent further drug resistance. To this end, antimycobacterial activity, mechanism of action, and synergism in combination therapy were investigated for a series of polycyclic amine derivatives. Compound selection was based on the presence of moieties with possible antimycobacterial activity, the inclusion of bulky lipophilic carriers to promote intracellular accumulation, and previously demonstrated bioactivity that potentially support inhibition of efflux pump activity. The most potent antimycobacterial demonstrated a minimum inhibitory concentration (MIC99) of 9.6 μM against Mycobacterium tuberculosis H37Rv. Genotoxicity and inhibition of the cytochrome bc1 respiratory complex were excluded as mechanisms of action for all compounds. Inhibition of cell wall synthesis was identified as a likely mechanism of action for the two most active compounds (14 and 15). Compounds 5 and 6 demonstrated synergistic activity with the known Rv1258c efflux pump substrate, spectinomycin, pointing to possible efflux pump inhibition. For this series, the nature of the side chain, rather than the type of polycyclic carrier, seems to play a determining role in the antimycobacterial activity and cytotoxicity of the compounds. Contrariwise, the nature of the polycyclic carrier, particularly the azapentacycloundecane cage, appears to promote synergistic activity. Results point to the possibility of combining an azapentacycloundecane carrier with a side chain that promotes antimycobacterial activity to develop dual acting molecules for the treatment of Mycobacterium tuberculosis. |
| format | Article |
| id | doaj-art-88c1c1f46efe44879b93b4033a581dc2 |
| institution | Kabale University |
| issn | 2633-4690 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Pharmacological and Pharmaceutical Sciences |
| spelling | doaj-art-88c1c1f46efe44879b93b4033a581dc22025-02-03T01:24:49ZengWileyAdvances in Pharmacological and Pharmaceutical Sciences2633-46902021-01-01202110.1155/2021/55833425583342Antimycobacterial Activity, Synergism, and Mechanism of Action Evaluation of Novel Polycyclic Amines against Mycobacterium tuberculosisErika Kapp0Jacques Joubert1Samantha L. Sampson2Digby F. Warner3Ronnett Seldon4Audrey Jordaan5Margaretha de Vos6Rajan Sharma7Sarel F. Malan8School of Pharmacy, Faculty of Natural Sciences, University of the Western Cape, Cape Town, South AfricaSchool of Pharmacy, Faculty of Natural Sciences, University of the Western Cape, Cape Town, South AfricaDSI/NRF Centre of Excellence for Biomedical Tuberculosis Research, SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, University of Stellenbosch, Cape Town, South AfricaSAMRC/NHLS/UCT Molecular Mycobacteriology Research Unit, DSI/NRF Centre of Excellence for Biomedical Tuberculosis Research, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South AfricaH3D Drug Discovery and Development Centre, Department of Chemistry, University of Cape Town, Cape Town, South AfricaSAMRC/NHLS/UCT Molecular Mycobacteriology Research Unit, DSI/NRF Centre of Excellence for Biomedical Tuberculosis Research, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South AfricaDSI/NRF Centre of Excellence for Biomedical Tuberculosis Research, SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, University of Stellenbosch, Cape Town, South AfricaSchool of Pharmacy, Faculty of Natural Sciences, University of the Western Cape, Cape Town, South AfricaSchool of Pharmacy, Faculty of Natural Sciences, University of the Western Cape, Cape Town, South AfricaMycobacterium tuberculosis has developed extensive resistance to numerous antimycobacterial agents used in the treatment of tuberculosis. Insufficient intracellular accumulation of active moieties allows for selective survival of mycobacteria with drug resistance mutations and accordingly promotes the development of microbial drug resistance. Discovery of compounds with new mechanisms of action and physicochemical properties that promote intracellular accumulation, or compounds that act synergistically with other antimycobacterial drugs, has the potential to reduce and prevent further drug resistance. To this end, antimycobacterial activity, mechanism of action, and synergism in combination therapy were investigated for a series of polycyclic amine derivatives. Compound selection was based on the presence of moieties with possible antimycobacterial activity, the inclusion of bulky lipophilic carriers to promote intracellular accumulation, and previously demonstrated bioactivity that potentially support inhibition of efflux pump activity. The most potent antimycobacterial demonstrated a minimum inhibitory concentration (MIC99) of 9.6 μM against Mycobacterium tuberculosis H37Rv. Genotoxicity and inhibition of the cytochrome bc1 respiratory complex were excluded as mechanisms of action for all compounds. Inhibition of cell wall synthesis was identified as a likely mechanism of action for the two most active compounds (14 and 15). Compounds 5 and 6 demonstrated synergistic activity with the known Rv1258c efflux pump substrate, spectinomycin, pointing to possible efflux pump inhibition. For this series, the nature of the side chain, rather than the type of polycyclic carrier, seems to play a determining role in the antimycobacterial activity and cytotoxicity of the compounds. Contrariwise, the nature of the polycyclic carrier, particularly the azapentacycloundecane cage, appears to promote synergistic activity. Results point to the possibility of combining an azapentacycloundecane carrier with a side chain that promotes antimycobacterial activity to develop dual acting molecules for the treatment of Mycobacterium tuberculosis.http://dx.doi.org/10.1155/2021/5583342 |
| spellingShingle | Erika Kapp Jacques Joubert Samantha L. Sampson Digby F. Warner Ronnett Seldon Audrey Jordaan Margaretha de Vos Rajan Sharma Sarel F. Malan Antimycobacterial Activity, Synergism, and Mechanism of Action Evaluation of Novel Polycyclic Amines against Mycobacterium tuberculosis Advances in Pharmacological and Pharmaceutical Sciences |
| title | Antimycobacterial Activity, Synergism, and Mechanism of Action Evaluation of Novel Polycyclic Amines against Mycobacterium tuberculosis |
| title_full | Antimycobacterial Activity, Synergism, and Mechanism of Action Evaluation of Novel Polycyclic Amines against Mycobacterium tuberculosis |
| title_fullStr | Antimycobacterial Activity, Synergism, and Mechanism of Action Evaluation of Novel Polycyclic Amines against Mycobacterium tuberculosis |
| title_full_unstemmed | Antimycobacterial Activity, Synergism, and Mechanism of Action Evaluation of Novel Polycyclic Amines against Mycobacterium tuberculosis |
| title_short | Antimycobacterial Activity, Synergism, and Mechanism of Action Evaluation of Novel Polycyclic Amines against Mycobacterium tuberculosis |
| title_sort | antimycobacterial activity synergism and mechanism of action evaluation of novel polycyclic amines against mycobacterium tuberculosis |
| url | http://dx.doi.org/10.1155/2021/5583342 |
| work_keys_str_mv | AT erikakapp antimycobacterialactivitysynergismandmechanismofactionevaluationofnovelpolycyclicaminesagainstmycobacteriumtuberculosis AT jacquesjoubert antimycobacterialactivitysynergismandmechanismofactionevaluationofnovelpolycyclicaminesagainstmycobacteriumtuberculosis AT samanthalsampson antimycobacterialactivitysynergismandmechanismofactionevaluationofnovelpolycyclicaminesagainstmycobacteriumtuberculosis AT digbyfwarner antimycobacterialactivitysynergismandmechanismofactionevaluationofnovelpolycyclicaminesagainstmycobacteriumtuberculosis AT ronnettseldon antimycobacterialactivitysynergismandmechanismofactionevaluationofnovelpolycyclicaminesagainstmycobacteriumtuberculosis AT audreyjordaan antimycobacterialactivitysynergismandmechanismofactionevaluationofnovelpolycyclicaminesagainstmycobacteriumtuberculosis AT margarethadevos antimycobacterialactivitysynergismandmechanismofactionevaluationofnovelpolycyclicaminesagainstmycobacteriumtuberculosis AT rajansharma antimycobacterialactivitysynergismandmechanismofactionevaluationofnovelpolycyclicaminesagainstmycobacteriumtuberculosis AT sarelfmalan antimycobacterialactivitysynergismandmechanismofactionevaluationofnovelpolycyclicaminesagainstmycobacteriumtuberculosis |